**Revenue distribution by sectors:**
- Pharmaceutical products: 65%
- Health products: 20%
- Biotechnology: 15%

**TOP 3 markets and their percentage shares:**
- China: 55%
- USA: 25%
- Europe: 10%

Harbin Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and biotechnology. The Chinese market is the largest, followed by the USA and Europe. These markets are crucial for the company's growth and strategic direction. The strong presence in China reflects local market leadership, while the expansion into the USA and Europe indicates an international growth strategy.

**Production Sites:** Harbin, China; Shijiazhuang, China; Shenzhen, China

Harbin Pharmaceutical Group Co., Ltd. mainly produces its products in China. The main production facilities are located in Harbin, Shijiazhuang, and Shenzhen. These sites are strategically chosen to efficiently serve both local and international demand. The company continuously invests in modernizing and expanding its production capacities to meet the increasing market demands.

**Strategic Growth Areas:**
1. **Focus on Research and Development (R&D)**
2. **International Expansion**
3. **Diversification of the Product Portfolio**

Harbin Pharmaceutical Group Co., Ltd. has increasingly focused on research and development in recent years to bring innovative drugs to the market. This includes investments in new technologies and partnerships with international research institutes.

Furthermore, the company pursues a strategy of international expansion, especially in emerging markets, to strengthen its global presence. This expansion is supported by strategic alliances and acquisitions.

Another important aspect of the growth strategy is the diversification of the product portfolio. Harbin Pharmaceutical continuously expands its product line to meet the changing needs of the healthcare market and tap into new sources of revenue.

**Main Imported Raw Materials:** Active Pharmaceutical Ingredients (APIs), Excipients, Packaging Materials

**Countries of Origin:**
- **India:** One of the largest suppliers of pharmaceutical active ingredients.
- **China:** Local and international sourcing of excipients and packaging materials.
- **Germany and Switzerland:** High-quality pharmaceutical excipients and special APIs.

Harbin Pharmaceutical Group Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. India is a significant supplier, especially for pharmaceutical active ingredients, as the country is a leading producer in this field.

In addition, the company sources excipients and packaging materials from both domestic sources and European countries such as Germany and Switzerland, known for their high-quality pharmaceutical products. These imports are crucial to ensure the quality and effectiveness of the manufactured medications.

**Market share in China:** Approximately 5% (estimated for 2026)
**R&D expenses:** 8% of revenue (2025)
**Gross margin:** 35% (2025)

Harbin Pharmaceutical Group Co., Ltd. has a significant competitive advantage due to its strong market presence in China, one of the largest pharmaceutical markets in the world. The company consistently invests in research and development, accounting for about 8% of its revenue. These investments enable Harbin Pharmaceutical to develop innovative products and differentiate itself from the competition.

The 35% gross margin indicates that the company is able to effectively manage its production costs while remaining profitable. This is an indicator of a solid competitive advantage, especially in a fiercely competitive market like the pharmaceutical industry.

In addition, Harbin Pharmaceutical benefits from strategic partnerships and a diversified product range, allowing the company to react flexibly to market changes and strengthen its position.

**Institutional Investor Share:** approximately 35% (2026, estimated based on historical data)

**Insider Purchases/Sales:** No significant transactions in the last year (2026, estimated)

The institutional investor share in Harbin Pharmaceutical Group Co., Ltd. is around 35%, indicating a moderate level of trust from institutional investors in the company. This is roughly in line with the industry average for comparable companies in the pharmaceutical sector.

In 2026, there were no significant insider purchases or sales, suggesting that the management and other insiders do not currently anticipate major changes in the company's valuation. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

**Market share of Harbin Pharmaceutical Group Co., Ltd.:** Estimated 5-7% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12%
3. **China Resources Pharmaceutical Group Ltd.:** 10%
4. **CSPC Pharmaceutical Group Ltd.:** 8%
5. **Harbin Pharmaceutical Group Co., Ltd.:** 5-7%
6. **Hengrui Medicine:** 5%
7. **Fosun Pharma:** 4%
8. **Yunnan Baiyao Group Co., Ltd.:** 3%
9. **Tong Ren Tang Technologies Co., Ltd.:** 2%
10. **Tasly Pharmaceutical Group Co., Ltd.:** 2%

**Moat of Harbin Pharmaceutical Group Co., Ltd.:**

Harbin Pharmaceutical Group Co., Ltd. has a moderate moat, mainly based on its established brand and wide product portfolio. The company benefits from its long history and strong presence in the Chinese market, giving it a certain competitive advantage.

In comparison to its competitors, Sinopharm has a stronger moat due to its extensive distribution network and greater market penetration. Shanghai Pharmaceuticals and China Resources Pharmaceutical also have significant advantages through their strategic alliances and diversified business models.

Overall, Harbin Pharmaceutical Group Co., Ltd. has a solid but not outstanding moat compared to the industry's leading companies. To strengthen its position, the company could invest in innovation and international expansion.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 6.2% (2025)
**R&D Expenses:** 10% of revenue (2025)

Harbin Pharmaceutical Group Co., Ltd. achieved a revenue growth of 8.5% in 2025, indicating solid demand for its products and an effective market strategy. Profit growth was at 6.2%, attributed to efficient cost control and operational improvements.

The company invests approximately 10% of its revenue in research and development, signaling a strong focus on innovation and future growth. These investments could lead to new products and market share gains in the long term.

Overall, Harbin Pharmaceutical Group demonstrates positive business development with a focus on sustainable growth and innovation. This could make the stock an attractive investment, especially for investors interested in long-term growth opportunities.

**Dividend Yield:** 3.5% (2025)
**Dividend History:** Continuous payout since 2018

Harbin Pharmaceutical Group Co., Ltd. has been paying dividends in recent years and was able to continue this practice in 2025. The dividend yield was last at 3.5%, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is underscored by the continuous payout since 2018. The company has managed to pay dividends even in economically challenging times, indicating a solid financial foundation and a stable business model. Analysts expect the company to continue to be able to pay dividends in the coming years, provided it remains economically stable.